NasdaqGS:ROIVBiotechs
How New Analyst Coverage Spotlighting Brepocitinib’s Phase 3 Readouts At Roivant Sciences (ROIV) Has Changed Its Investment Story
In April 2026, Piper Sandler and Bernstein initiated coverage on Roivant Sciences, emphasizing the company’s inflammation and immunology pipeline, including late-stage programs such as brepocitinib across multiple immune-mediated diseases.
This fresh analyst attention places brepocitinib’s upcoming dermatomyositis, non-infectious uveitis, and cutaneous sarcoidosis readouts at the center of Roivant’s medium-term outlook.
We’ll now examine how this renewed focus on brepocitinib’s upcoming...